Oral contraceptives and venous thrombosis. An ... - Ãjvind Lidegaard

More documents

Recommendations

Info

ObjectivesOC axesConfoundersDose of estrogenDuration of useVTEriskAgeYearType of progestagenEducation<strong>Lidegaard</strong> et al. BMJ 2011; 343: d6423
InclusionMaterial• All women in Denmark 15-49 years oldduring the period January 1995 throughDecember 2009 (15 years)• Study focus: 2001-2009; after launch of OCwith drospirenone.• Data from four National registries:<strong>Lidegaard</strong> et al. BMJ 2011; 343: d6423
Page 1 and 2: Oral contraceptionand venous thromb
Page 3 and 4: COC DK 2009: Progestogen typesCypro
Page 6: OC and VTE: Progestagen typeadjuste
Page 9 and 10: VTE and drospirenoneVTE Risk Rate r
Page 11 and 12: Research story• 1960s: OC were in
Page 13 and 14: Preliminary AgendaDefinitions• We
Page 16 and 17: Critique In the Danish study the co
Page 18 and 19: EditorialGrimes, Obstet Gynecol Nov
Page 20 and 21: Research using vital Definitionsrec
Page 22 and 23: Research story• 2010, Jan: Shapir
Page 24 and 25: Research story• 2010, Jan: Shapir
Page 27: Oral contraception and VTEA Nationa
Page 31 and 32: MaterialExclusions (
Page 33 and 34: Risk of VTE according to yearAdjust
Page 35 and 36: Relative risk versus non-useRate ra
Page 41 and 42: VTE and drospirenoneVTE IR Rate rat
Page 43 and 44: HC and VTE according to oestrogendo
Page 45 and 46: VTE and drospirenoneVTE IR Rate rat
Page 47 and 48: Blomenkamp88-92WHO1989-93Jick1991-9
Page 49 and 50: OCs and SHBG changes400% increase i
Page 51 and 52: COC and VTE: Conclusion• COC incr
Page 53 and 54: CT, AMI and VTE in DK 2001-2009Preg
Page 55 and 56: COC and VTE: Perspectives• Parent
Page 57 and 58: COC and VTE: Perspectives• Parent
Page 59: COC and VTE: PerspectivesThankswww.

Oral contraceptives and venous thrombosis. An ... - Ãjvind Lidegaard

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?

Oral contraceptives and venous thrombosis. An ... - Ãjvind Lidegaard